Three Cell And Gene Therapies Reach Critical Review Stage In EU
BMS, bluebird bio And PTC Therapeutics Need To Address Reviewers' Outstanding Issues
A number of advanced therapies are likely to be approved in the EU this year.
A number of advanced therapies are likely to be approved in the EU this year.